Classical Hodgkin lymphoma stage III-IV (advanced) — selects A+AVD (ECHELON-1) over ABVD...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-CHL-ADVANCED-STAGE`
Type	Red flag
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-CHL`
Sources	`SRC-ESMO-HODGKIN-2024` `SRC-NCCN-BCELL-2025`

Red Flag Origin

Definition	Classical Hodgkin lymphoma stage III-IV (advanced) — selects A+AVD (ECHELON-1) over ABVD if brentuximab accessible
Clinical direction	intensify
Category	high-risk-biology
Shifts algorithm	ALGO-CHL-1L

Trigger Logic

{
  "any_of": [
    {
      "finding": "stage_3_or_4",
      "value": true
    },
    {
      "finding": "advanced_stage_chl",
      "value": true
    }
  ],
  "type": "composite_clinical"
}

Used By

Algorithms

ALGO-CHL-1L - ALGO-CHL-1L
ALGO-CHL-2L - ALGO-CHL-2L

Indications

IND-CHL-1L-ABVD - IND-CHL-1L-ABVD
IND-CHL-1L-N-AVD - IND-CHL-1L-N-AVD

Red flag

RF-PRIOR-BV-NAIVE - Patient has NOT previously received brentuximab vedotin (BV) — eligible for BV-containing...